Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co., Ltd., following its reimbursement listing on Japan's National Health Insurance (NHI) price list. Elevidys is the first gene therapy to be launched in Japan for Duchenne muscular dystrophy (DMD). In Japan, ELEVIDYS is available for ambulatory indivi.

Business Wire • 11 hours ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Mass. on Tuesday, March 3 at 1:50 p.m. E.T. The presentations will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-.

Business Wire • 12 hours ago

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 18, 2026

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website a.

Business Wire • Feb 11, 2026

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, has granted approval for its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT. Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investigational sm.

Business Wire • Feb 4, 2026

SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD

SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.

Zacks Investment Research • Jan 27, 2026

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Sarepta Therapeutics' gene therapy for a progressive muscle‑wasting disorder showed sustained benefit in patients' ability to control and coordinate movement, according to three‑year data from a late‑stage study released on Monday.

Reuters • Jan 26, 2026

Sarepta Pops On Elevidys Data; But Will It Save The Embattled Gene Therapy?

Sarepta stock jumped early Monday after the company unveiled three-year test results for its embattled gene therapy, Elevidys.

Investors Business Daily • Jan 26, 2026

Sarepta Therapeutics shares rise on positive Duchenne gene therapy data

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from its Phase 3 EMBARK study evaluating its gene therapy ELEVIDYS in ambulatory patients with Duchenne muscular dystrophy. Sarepta said patients treated with ELEVIDYS demonstrated statistically significant and clinically meaningful slowing of disease progression across key functional measures compared with an untreated external control group.

Proactive Investors • Jan 26, 2026

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Seeking Alpha • Jan 26, 2026